Talidomid (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Talidomid" in Polish language version.

refsWebsite

Global rank Polish rank

8doi.org

2^nd place

6^th place

6nih.gov

4^th place

7^th place

2worldcat.org

5^th place

2^nd place

2termedia.pl

low place

624^th place

1web.archive.org

1^st place

1fda.gov

447^th place

1,118^th place

1who.int

195^th place

256^th place

1medicines.org.uk

3,823^rd place

low place

doi.org

dx.doi.org

John C.J.C. Reepmeyer John C.J.C., Separation of R- and S-Thalidomide by Reversed-Phase HPLC with β-cyclodextrin in the mobile phase, „Chirality”, 8 (1), 1996, s. 11–17, DOI: 10.1002/(SICI)1520-636X(1996)8:13.0.CO;2-J, ISSN 1520-636X [dostęp 2020-12-29] (ang.).
John C.J.C. Reepmeyer John C.J.C. i inni, Characterization and crystal structure of two polymorphic forms of racemic thalidomide, „Journal of the Chemical Society, Perkin Transactions 2” (9), 1994, s. 2063, DOI: 10.1039/p29940002063, ISSN 0300-9580 [dostęp 2020-12-29] (ang.).
P.P. Skowronek P.P., J.J. Gawroński J.J., Absolute configuration of α-phthalimido carboxylic acid derivatives from circular dichroism spectra, „Tetrahedron: Asymmetry”, 10 (23), 1999, s. 4585–4590, DOI: 10.1016/S0957-4166(99)00521-2 [dostęp 2020-12-29] (ang.).
GottfriedG. Blaschke GottfriedG., Horst-PeterH.P. Kraft Horst-PeterH.P., HildegundeH. Markgraf HildegundeH., Chromatographische Racemattrennungen, X. Racemattrennung des Thalidomids und anderer Glutarimid-Derivate, „Chemische Berichte”, 113 (6), 1980, s. 2318–2322, DOI: 10.1002/cber.19801130626 (niem.).
AtsushiA. Shoji AtsushiA. i inni, Modified DNA aptamer that binds the (R)-isomer of a thalidomide derivative with high enantioselectivity, „Journal of the American Chemical Society”, 129 (5), 2007, s. 1456–1464, DOI: 10.1021/ja067098n, PMID: 17263432 .
H.P.H.P. Koch H.P.H.P., M.J.M.J. Czejka M.J.M.J., Evidence for the intercalation of thalidomide into DNA: clue to the molecular mechanism of thalidomide teratogenicity?, „Zeitschrift Fur Naturforschung. C”, 41 (11-12), 1986, s. 1057–1061, DOI: 10.1515/znc-1986-11-1218, PMID: 2953123 (ang.).
TakumiT. Ito TakumiT. i inni, Identification of a primary target of thalidomide teratogenicity, „Science”, 327 (5971), 2010, s. 1345–1350, DOI: 10.1126/science.1177319, PMID: 20223979 (ang.).
P.S.P.S. Haas P.S.P.S. i inni, Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses, „European Journal of Haematology”, 80 (4), 2008, s. 303–309, DOI: 10.1111/j.1600-0609.2007.01022.x, PMID: 18182082 (ang.).

fda.gov

Frances OldhamF.O. Kelsey Frances OldhamF.O., FDA Medical Reviewer Leaves Her Mark on History, „FDA Consumer Magazine”, 2001 [zarchiwizowane z adresu 2009-01-18] (ang.).

medicines.org.uk

Thalidomide Celgene 50 mg Hard Capsules - Summary of Product Characteristics (SmPC) - (eMC) [online], www.medicines.org.uk [dostęp 2020-12-29] .

nih.gov

ncbi.nlm.nih.gov

YuichiY. Ando YuichiY., EiichiE. Fuse EiichiE., William D.W.D. Figg William D.W.D., Thalidomide metabolism by the CYP2C subfamily, „Clinical Cancer Research”, 8 (6), 2002, s. 1964–1973, PMID: 12060642 (ang.).
AtsushiA. Shoji AtsushiA. i inni, Modified DNA aptamer that binds the (R)-isomer of a thalidomide derivative with high enantioselectivity, „Journal of the American Chemical Society”, 129 (5), 2007, s. 1456–1464, DOI: 10.1021/ja067098n, PMID: 17263432 .
H.P.H.P. Koch H.P.H.P., M.J.M.J. Czejka M.J.M.J., Evidence for the intercalation of thalidomide into DNA: clue to the molecular mechanism of thalidomide teratogenicity?, „Zeitschrift Fur Naturforschung. C”, 41 (11-12), 1986, s. 1057–1061, DOI: 10.1515/znc-1986-11-1218, PMID: 2953123 (ang.).
TakumiT. Ito TakumiT. i inni, Identification of a primary target of thalidomide teratogenicity, „Science”, 327 (5971), 2010, s. 1345–1350, DOI: 10.1126/science.1177319, PMID: 20223979 (ang.).
P.S.P.S. Haas P.S.P.S. i inni, Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses, „European Journal of Haematology”, 80 (4), 2008, s. 303–309, DOI: 10.1111/j.1600-0609.2007.01022.x, PMID: 18182082 (ang.).

dailymed.nlm.nih.gov

Thalomid - thalidomide capsule [online], dailymed.nlm.nih.gov, 19 września 2019 [dostęp 2020-12-29] .

termedia.pl

MałgorzataM. Rokicka-Piotrowicz MałgorzataM., Talidomid w leczeniu szpiczaka mnogiego, „Współczesna Onkologia”, 5 (4), 2001, s. 161-164 [dostęp 2020-12-29] .
AndrzejA. Hellmann AndrzejA. i inni, Talidomid w monoterapii oraz w połączeniu z deksametazonem u chorych z oporną postacią szpiczaka mnogiego, „Współczesna Onkologia”, 5 (6), 2001, s. 273–277 [dostęp 2020-12-29] .

web.archive.org

Frances OldhamF.O. Kelsey Frances OldhamF.O., FDA Medical Reviewer Leaves Her Mark on History, „FDA Consumer Magazine”, 2001 [zarchiwizowane z adresu 2009-01-18] (ang.).

who.int

Use of thalidomide in leprosy [online], WHO [dostęp 2019-04-02] (ang.).

worldcat.org

John C.J.C. Reepmeyer John C.J.C., Separation of R- and S-Thalidomide by Reversed-Phase HPLC with β-cyclodextrin in the mobile phase, „Chirality”, 8 (1), 1996, s. 11–17, DOI: 10.1002/(SICI)1520-636X(1996)8:13.0.CO;2-J, ISSN 1520-636X [dostęp 2020-12-29] (ang.).
John C.J.C. Reepmeyer John C.J.C. i inni, Characterization and crystal structure of two polymorphic forms of racemic thalidomide, „Journal of the Chemical Society, Perkin Transactions 2” (9), 1994, s. 2063, DOI: 10.1039/p29940002063, ISSN 0300-9580 [dostęp 2020-12-29] (ang.).